← The SEC Ephemeris: the whole map
Eli Lilly and Company lebrikizumab
In the graph: all 12 documents (186 pages).
- Application
- BLA 761306
- Ticker
- LLY
- Product
- lebrikizumab
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- September 28, 2023 · March 30, 2023 · January 18, 2023 · December 17, 2021 · December 17, 2021
From FDA letters and SEC filings. Not investment or medical advice.